Biotage AB (publ)

OM:BIOT Stock Report

Market Cap: SEK 12.7b

Biotage Valuation

Is BIOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIOT (SEK158.8) is trading below our estimate of fair value (SEK292.54)

Significantly Below Fair Value: BIOT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOT?

Key metric: As BIOT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIOT. This is calculated by dividing BIOT's market cap by their current earnings.
What is BIOT's PE Ratio?
PE Ratio49.5x
EarningsSEK 257.00m
Market CapSEK 12.71b

Price to Earnings Ratio vs Peers

How does BIOT's PE Ratio compare to its peers?

The above table shows the PE ratio for BIOT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average69.3x
ALIF B AddLife
142.9x52.0%SEK 16.7b
MCAP MedCap
39xn/aSEK 8.9b
GENO Genovis AB (publ.)
58.6x16.4%SEK 1.6b
MAGLE Magle Chemoswed Holding
36.5xn/aSEK 610.9m
BIOT Biotage
49.5x19.5%SEK 12.7b

Price-To-Earnings vs Peers: BIOT is good value based on its Price-To-Earnings Ratio (49.5x) compared to the peer average (69.3x).

Price to Earnings Ratio vs Industry

How does BIOT's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
BIOT 49.5xIndustry Avg. 38.6xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIOT is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the European Life Sciences industry average (38.6x).

Price to Earnings Ratio vs Fair Ratio

What is BIOT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.5x
Fair PE Ratio43.8x

Price-To-Earnings vs Fair Ratio: BIOT is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIOT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 158.80
SEK 202.67
+27.6%
3.4%SEK 212.00SEK 196.00n/a3
Dec ’25SEK 152.30
SEK 202.67
+33.1%
3.4%SEK 212.00SEK 196.00n/a3
Nov ’25SEK 158.50
SEK 190.67
+20.3%
11.7%SEK 212.00SEK 160.00n/a3
Oct ’25SEK 184.50
SEK 193.33
+4.8%
12.9%SEK 220.00SEK 160.00n/a3
Sep ’25SEK 197.20
SEK 191.00
-3.1%
11.8%SEK 213.00SEK 160.00n/a3
Aug ’25SEK 194.50
SEK 191.00
-1.8%
11.8%SEK 213.00SEK 160.00n/a3
Jul ’25SEK 160.90
SEK 190.00
+18.1%
11.4%SEK 210.00SEK 160.00n/a3
Jun ’25SEK 185.40
SEK 173.33
-6.5%
10.9%SEK 200.00SEK 160.00n/a3
May ’25SEK 168.00
SEK 186.67
+11.1%
10.1%SEK 200.00SEK 160.00n/a3
Apr ’25SEK 181.90
SEK 186.67
+2.6%
10.1%SEK 200.00SEK 160.00n/a3
Mar ’25SEK 176.50
SEK 186.67
+5.8%
10.1%SEK 200.00SEK 160.00n/a3
Feb ’25SEK 143.70
SEK 165.33
+15.1%
4.6%SEK 176.00SEK 160.00n/a3
Jan ’25SEK 133.70
SEK 155.00
+15.9%
3.2%SEK 160.00SEK 150.00n/a2
Dec ’24SEK 125.00
SEK 155.00
+24.0%
3.2%SEK 160.00SEK 150.00SEK 152.302
Nov ’24SEK 114.60
SEK 155.00
+35.3%
3.2%SEK 160.00SEK 150.00SEK 158.502
Apr ’24SEK 132.20
SEK 211.50
+60.0%
24.3%SEK 263.00SEK 160.00SEK 181.902
Mar ’24SEK 149.80
SEK 254.00
+69.6%
3.5%SEK 263.00SEK 245.00SEK 176.502
Feb ’24SEK 163.10
SEK 239.00
+46.5%
10.0%SEK 263.00SEK 215.00SEK 143.702
Jan ’24SEK 185.50
SEK 249.00
+34.2%
5.6%SEK 263.00SEK 235.00SEK 133.702
Dec ’23SEK 189.30
SEK 249.00
+31.5%
5.6%SEK 263.00SEK 235.00SEK 125.002

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:52
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biotage AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Odysseas ManesiotisBerenberg
Marcus BellanderCarnegie Investment Bank AB